Dilbert creator Scott Adams provided a major health update from the hospital, revealing the medicine he asked Donald Trump to ...

Prostate, lung, and breast cancer alone account for over $60 billion in annual drug spending, yet resistance to current therapies continues to create costly failures. Actinium Pharmaceuticals (NYSE ...

Sartorius Group is expected to continue delivering high-single digit CER sales growth in 2026, supported by strong consumables performance. JPMorgan maintains an Overweight rating with price targets ...

A closer look at phase 3 data on BioNTech and OncoC4’s anti-CTLA-4 antibody has shown the efficacy that excited analysts last ...

But the biotech’s newest update has failed to garner the same investor enthusiasm, with the company’s stock nearly halved following the data drop.

Janux posts what it called ‘positive trial data’ for its novel treatment in patients with late-stage prostate cancer.

Janux Therapeutics is now rated Hold after recent JANX007 Phase 1 data failed to show clear differentiation in mCRPC. Read my ...

Actinium Pharmaceuticals, Inc. , a leader in the development of differentiated targeted radiotherapies, today announced compelling preclinical data for ATNM-400, a first-in-class Actinium-225 (AC-225) ...

The shares on their own merits are not cheap, but then the range of valuations in European pharma is wider than it has been for many years. Novartis currently trades at a FactSet-compiled 2026 ...

Detailed price information for Actinium Pharmaceuticals Inc (ATNM-A) from The Globe and Mail including charting and trades.

Pluvicto TM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic ...